COMPANY PROFILE

Allay Therapeutics

Explore full profile

Offers analgesic products for post-surgical pain management and recuperation

Menlo Park, United StatesFounded 2017Biotech & Life Sciences

Valuation $250–500M Last recorded · 2025

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Allay Therapeutics

Allay Therapeutics is at the forefront of developing ultra sustained analgesic products aimed at revolutionizing post-surgical pain management and recovery. The company targets both patients and physicians by providing longer-lasting, safer, and more tailored pain relief solutions. Operating primarily in the healthcare and pharmaceutical sectors, Allay Therapeutics focuses on creating innovative therapies that address the significant challenges in post-surgical pain management. Their business model involves the research, development, and clinical testing of proprietary pain management products, such as their lead candidate ATX101, which is currently in Phase 2 clinical trials for total knee arthroplasty (TKA) surgeries. Revenue is generated through the commercialization of these therapeutic products, once approved, and potential partnerships or licensing agreements with other pharmaceutical companies. The company operates globally, with a presence in both the San Francisco Bay Area and Singapore, and is driven by a culture of scientific excellence and innovation.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Menlo Park, United States
Employees: 36
Open positions: None listed
Dealroom signal: 62.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
DEBTDebt	Jun 2025	$0	—	HSBC Innovation Banking	↗
SERIES DOther financing	Jun 2025	$58M	$230M	NEA · Vertex Ventures HC · Vertex Growth Fund · IPD Capital	↗

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Allay Therapeutics website traffic

Latest recorded traffic for Allay Therapeutics is 1K monthly website visits, down 37.5% over the last three months. Allay Therapeutics's team declined 30.8% over the past year.

Latest monthly visits1K 3-month web change-37.5% 1-year team growth-30.8%

Monthly website visitsOct 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
HTHarness TherapeuticsA private biotechnology company, headquartered in Cambridge-UK, focused on the development of a novel class of therapeutic RNAs	Babraham, United Kingdom	Operational	5	$35M	$90M
KIKimialysDeveloper of an analytical device intended to offer products based on innovative surface chemistry in the field of biosensors	Paris, France	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
ANAntegenesGenetic tests for personalized cancer risk prevention	Tartu, Estonia	Operational
BPBrenus PharmaProducing the widest panel of tumor associated antigens and resistance markers with a chemical labeling enable to induce cell death by patients' immune system	Clermont-Ferrand, France	Operational
EBExeliom BiosciencesDeveloping single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics	Dijon, France	Operational
MTModalis TherapeuticsEpigenetic gene modulation therapies for genetic disorders	Cambridge, United States	Operational
HPHcs PharmaA company specializing in cell imaging	Loos, France	Operational